Respiratory News and Research

RSS

Invacare reports net loss per share of $0.19 in fourth quarter 2013

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2013.

6 Feb 2014

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

New research shows that children with febrile status epilepticus (FSE) who receive earlier treatment with antiepileptic drugs (AEDs) experience a reduction in the duration of the seizure.

6 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Overweight, obese adults can breathe 7-50% more air per day than adult with healthy weight

Overweight or obese adults can breathe 7-50% more air per day than an adult with healthy weight does, which makes them more vulnerable to air contaminants causing asthma and other pulmonary diseases, according to a study by Dr. Pierre Brochu, a professor at Université de Montréal's School of Public Health.

5 Feb 2014

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia.

4 Feb 2014

Study reveals link between neonatal and early childhood outcomes among premature infants

In a study to be presented on Feb. 6 at 3:15 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting-, in New Orleans, researchers will report on a correlation between initial neonatal and early childhood outcomes among children delivered less than 34 weeks gestation.

4 Feb 2014

Findings recommend expectant monitoring for women with gestational hypertension

In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.

4 Feb 2014

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold.

3 Feb 2014

Parents of children with disabilities more likely to suffer from chronic health conditions

A University of Limerick study has found that parents of children with learning or developmental disabilities have an increased risk of depression and are more likely to suffer from chronic health conditions. The figures showed that 15% of parents of children with disabilities were classified as depressed and unfortunately less than half of them reported being treated for depression.

3 Feb 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

The first clinical study of a low-cost neonatal breathing system created by Rice University bioengineering students demonstrated that the device increased the survival rate of newborns with severe respiratory illness from 44 percent to 71 percent.

31 Jan 2014

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

The American Association of Critical-Care Nurses (AACN) — as part of the Critical Care Societies Collaborative (CCSC) — has identified five routine critical care practices that should be questioned because they may not always be necessary and could, in fact, be harmful.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

The flu season is in full swing starting mostly in the second week of January when emergency rooms are more busy than usual with patient with flu like symptoms. Dr. James Kojian, E.R. expert and founder of DRTOHELP.COM, warns the public about five things your doctor may be doing wrong when treating for the flu.

25 Jan 2014

NJHA honors several individuals and organizations for commitment to healthcare

Several individuals and organizations were honored today at the 95th Annual Meeting of the New Jersey Hospital Association at the Hyatt Regency Princeton.

24 Jan 2014

Respiratory News and Research

Invacare reports net loss per share of $0.19 in fourth quarter 2013

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Researchers design new vaccine for human-infecting respiratory syncytial virus

Overweight, obese adults can breathe 7-50% more air per day than adult with healthy weight

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Study reveals link between neonatal and early childhood outcomes among premature infants

Findings recommend expectant monitoring for women with gestational hypertension

URTI risk factor for chronic, recurrent otitis media

Parents of children with disabilities more likely to suffer from chronic health conditions

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

S. pneumoniae predicts acute sinusitis microbial response

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

NJHA honors several individuals and organizations for commitment to healthcare

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News